Development and Validation of Harbinger Health Test for Early Cancer Detection

Launched by HARBINGER HEALTH · Jun 27, 2022

Keywords

ClinConnect Summary

The clinical trial titled "Development and Validation of Harbinger Health Test for Early Cancer Detection" is studying a new test that aims to detect cancer early by analyzing blood and tissue samples. The goal is to gather information from about 10,000 participants across various locations in the United States. These participants will include individuals who have been diagnosed with different types of cancer as well as those who are healthy and do not have any signs of cancer. By comparing these two groups, researchers hope to develop a reliable screening test for early cancer detection.

To be eligible for this study, participants need to be between the ages of 20 and 79. If you have a confirmed or suspected cancer diagnosis that hasn’t been treated yet, you may qualify for the cancer group. Alternatively, if you are healthy and have not been diagnosed with cancer in the last five years, you could join the non-cancer group. Participants will have their blood and tissue samples collected, and they will be monitored for their health throughout the study. It’s important to note that this trial is currently recruiting participants, and you would need to give your consent before taking part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Inclusion Criteria - Both arms
• Subjects must meet the following criteria in order to be included in the research study:
• • Written or electronic informed consent
• • Subject is 20 - 79 years of age at the time of signature of the informed consent form (ICF)
• • Male or female subjects
• • Inclusion Criteria Arm 1 - Cancer Subjects Arm 1 subjects enrolled in the study must meet the following inclusion criteria.
• • A confirmed diagnosis or high suspicion of cancer (stage I to IV solid cancer or hematologic cancer) by imaging within 180 days prior to enrollment; not to include myelodysplastic and myeloproliferative syndromes
• • Subject's cancer diagnosis is based upon assessment of a pathological specimen or high suspicion of cancer by imaging
• • Subject's cancer is treatment-naïve
• • Inclusion Criteria Arm 2 - Non-Cancer Subjects (All Cohorts)
• Arm 2 subjects enrolled in the study must meet the following inclusion criteria:
• • Subject's health permits participation and the subject is not suspected of having cancer based on provider assessment.
• • The subject was not diagnosed with cancer or received cancer treatment within the last 5 years (persons with completely resected ductal carcinoma in-situ or non-melanoma skin cancer are permitted).
• Part 1B Only :
• - Subject has no known current cancer and has 1 of the follow conditions:
• • o An Advanced Adenoma (AA) of the gastrointestinal tract as defined as an adenoma that is ≤10mm in size Subjects with any one of the criteria would be eligible High grade displasia or ≥10 adenoma: any size Tubulovillous adenoma, any size Tubular adenoma ≥10mm Traditional serrated adenoma ≥10mm
• Exclusion Criteria:
• • Subject self-reporting OR available medical records at the time of screening are acceptable for assessment of all exclusion criteria.
• • Exclusion Criteria - Both arms
• Subjects who meet any of the following criteria will be excluded from study entry:
• • Subject is suffering from any febrile illness defined as a temperature \>101.5°F within the last 48 hrs.
• • Subject is pregnant (by self-report of pregnancy status).
• • Exclusion Criteria Arm 1 - Cancer Subjects
• Subjects who meet any of the following criteria will be excluded from study entry:
• • Subject with a prior history of cancer within 5 years will not be allowed to participate in the study
• • More than 1 active cancer diagnosis (ie. a subject presenting with recurrent breast cancer and newly diagnosed lung cancer would be excluded; subject with prior (\>5 years ago) treated breast cancer without recurrence and presenting with newly diagnosed lung cancer would be eligible).
• * Subject is currently receiving, or has in the past received, any of the following definitive therapies to treat their current cancer:
• • Surgical treatment, surgical removal, or surgical management of the cancer beyond that required to establish the cancer diagnosis. Surgical or biopsy procedures that remove more tissue than required to establish the cancer diagnosis, or that were performed to manage symptoms or initiate cancer treatment prior to blood sample collection will be considered 'definitive' and are not permissible regardless of the residual tumor mass remaining in the subject.
• • Chemotherapy (local, regional, or systemic) including chemoembolization targeted therapy;
• • Immunotherapy including cancer vaccines;
• • Hormone therapy; or
• • Radiation therapy (a single dose of palliative radiation prior to study start is allowed).
• • The subject is a recipient of an organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
• • Subject who has undergone a bowel preparation for a gastrointestinal malignancy within 3 days of an anticipated blood draw.
• • Exclusion Criteria Arm 2 - Non-cancer Subjects
• Subjects who meet any of the following criteria will be excluded from study entry:
• • - The subject is the recipient of an organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.